3918 related articles for article (PubMed ID: 18784090)
1. 10-year follow-up of intensive glucose control in type 2 diabetes.
Holman RR; Paul SK; Bethel MA; Matthews DR; Neil HA
N Engl J Med; 2008 Oct; 359(15):1577-89. PubMed ID: 18784090
[TBL] [Abstract][Full Text] [Related]
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up after tight control of blood pressure in type 2 diabetes.
Holman RR; Paul SK; Bethel MA; Neil HA; Matthews DR
N Engl J Med; 2008 Oct; 359(15):1565-76. PubMed ID: 18784091
[TBL] [Abstract][Full Text] [Related]
4. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Lancet; 1998 Sep; 352(9131):854-65. PubMed ID: 9742977
[TBL] [Abstract][Full Text] [Related]
5. [United Kingdom Prospective Diabetes Study (UKPDS): 10 years later].
Scheen AJ; Paquot N; Lefebvre PJ
Rev Med Liege; 2008 Oct; 63(10):624-9. PubMed ID: 19009971
[TBL] [Abstract][Full Text] [Related]
6. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524
[TBL] [Abstract][Full Text] [Related]
7. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
Turner RC; Cull CA; Frighi V; Holman RR
JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
[TBL] [Abstract][Full Text] [Related]
8. Glucose control and vascular complications in veterans with type 2 diabetes.
Duckworth W; Abraira C; Moritz T; Reda D; Emanuele N; Reaven PD; Zieve FJ; Marks J; Davis SN; Hayward R; Warren SR; Goldman S; McCarren M; Vitek ME; Henderson WG; Huang GD;
N Engl J Med; 2009 Jan; 360(2):129-39. PubMed ID: 19092145
[TBL] [Abstract][Full Text] [Related]
9. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus.
Turner R; Cull C; Holman R
Ann Intern Med; 1996 Jan; 124(1 Pt 2):136-45. PubMed ID: 8554206
[TBL] [Abstract][Full Text] [Related]
10. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91).
Adler AI; Coleman RL; Leal J; Whiteley WN; Clarke P; Holman RR
Lancet; 2024 May; ():. PubMed ID: 38772405
[TBL] [Abstract][Full Text] [Related]
11. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
Meneghini LF; Traylor L; Schwartz SL
Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
[TBL] [Abstract][Full Text] [Related]
12. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
13. [Should the occurrence of a first coronary event change the management of diabetes?].
Timsit J; Dubois-Laforgue D
Arch Mal Coeur Vaiss; 2000 Dec; 93 Spec No 4():39-44. PubMed ID: 11296461
[TBL] [Abstract][Full Text] [Related]
14. Glucose supply and insulin demand dynamics of antidiabetic agents.
Monte SV; Schentag JJ; Adelman MH; Paladino JA
J Diabetes Sci Technol; 2010 Mar; 4(2):365-81. PubMed ID: 20307399
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus.
Kooy A; de Jager J; Lehert P; Bets D; Wulffelé MG; Donker AJ; Stehouwer CD
Arch Intern Med; 2009 Mar; 169(6):616-25. PubMed ID: 19307526
[TBL] [Abstract][Full Text] [Related]
16. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group.
Diabetes Care; 1998 Jan; 21(1):87-92. PubMed ID: 9538975
[TBL] [Abstract][Full Text] [Related]
17. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years.
BMJ; 1995 Jan; 310(6972):83-8. PubMed ID: 7833731
[TBL] [Abstract][Full Text] [Related]
18. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
; Patel A; MacMahon S; Chalmers J; Neal B; Billot L; Woodward M; Marre M; Cooper M; Glasziou P; Grobbee D; Hamet P; Harrap S; Heller S; Liu L; Mancia G; Mogensen CE; Pan C; Poulter N; Rodgers A; Williams B; Bompoint S; de Galan BE; Joshi R; Travert F
N Engl J Med; 2008 Jun; 358(24):2560-72. PubMed ID: 18539916
[TBL] [Abstract][Full Text] [Related]
19. Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73.
Wright AD; Cull CA; Macleod KM; Holman RR;
J Diabetes Complications; 2006; 20(6):395-401. PubMed ID: 17070446
[TBL] [Abstract][Full Text] [Related]
20. A summary of the ADVANCE Trial.
Heller SR;
Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S357-61. PubMed ID: 19875581
[No Abstract] [Full Text] [Related]
[Next] [New Search]
